GLS-1 inhibition alone or in combination with immune checkpoint blockade represents an effective therapeutic strategy for SWI/SNF-altered cancers such as ARID1A-mutated ovarian clear cell carcinoma [45, 46]. This evidence concerns the gene ARID1A and ovarian clear cell cancer.